论文部分内容阅读
目的：为了研究赛若金（干扰素）在慢性病毒性肝病治疗中的合理应用及赛若金对慢性病毒性肝病的疗效比较。方法：对２１例ＨＢＶＤＮＡ、ＨＢｅＡｇ阳性的慢性乙型病毒性肝病患者，７例ＨＢＶＤＮＡ、ＨＢｅＡｇ阳性无症状携带者及８例ＨＣＶＲＮＡ阳性慢性丙型肝炎患者应用赛若金３～６Ｕ，每日１次肌注，１５～３０ｄ后隔日１次肌注，治疗３～６个月。结果：２１例慢性乙肝病毒性肝病患者疗程ＨＢＶＤＮＡ阴转率３个月时为３３３％，６个月时为４７６％；ＨＢｅＡｇ阴转率３个月时为３８１％，６个月时为５７１％。７例乙肝病毒携带者ＨＢＶＤＮＡ阴转率３个月时为２８６％，６个月时为４２９％。８例慢性丙肝患者ＨＣＶＲＮＡ阴转率３个月时为１２５％，６个月时为２５０％，明显高于常规治疗组（Ｐ＜００１）。应用赛若金治疗组大多数患者ＡＬＴ与ＡＳＴ水平恢复较快。结论：赛若金抑制病毒作用与疗程密切相关，抗病毒治疗疗效肯定。
OBJECTIVE: To investigate the rational use of safrancir (IFN) in the treatment of chronic viral liver disease and compare the efficacy of racecin in chronic viral liver disease. Methods: 21 cases of HBV DNA, HBeAg-positive chronic hepatitis B patients, 7 cases of HBV DNA, HBeAg positive asymptomatic carriers and 8 cases of HCV RNA positive chronic hepatitis C patients with Sajin 3 ~ 6U, intramuscular once a day, intramuscular injection every other day after 15 ~ 30d, 3 to 6 months. Results: In 21 cases of chronic hepatitis B patients, HBVDNA negative conversion rate was 333% at 3 months and 476% at 6 months. The negative conversion rate of HBeAg was 381% at 3 months , 57 1% at 6 months. Seven cases of hepatitis B virus HBV DNA negative conversion rate of 3 months when 28.6%, 6 months, 42.9%. 8 cases of chronic hepatitis C patients HCV RNA negative conversion rate of 3 months when 12 5%, 6 months was 25 0%, significantly higher than the conventional treatment group (P <0 01). ALT and AST levels recovered rapidly in most patients treated with racecin. Conclusion: Saurin inhibition of the virus is closely related with the course of treatment, anti-viral treatment efficacy is positive.